Indeed, when we treated THP-1 cells with increasing concentrations (10–1000 nM) of five different MTAs used in the treatment of breast cancer, we found that only the microtubule destabilizers (eribulin and vinorelbine) but not stabilizers (ixabepilone, paclitaxel, and docetaxel) upregulated IFNβ expression (Fig. 5D). This evidence concerns the gene IFNB1 and breast carcinoma.